<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241552</url>
  </required_header>
  <id_info>
    <org_study_id>3415A-001</org_study_id>
    <nct_id>NCT01241552</nct_id>
  </id_info>
  <brief_title>A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)</brief_title>
  <acronym>MODIFY I</acronym>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate whether: 1) treatment with MK-3415A in addition to standard of
      care (SOC) antibiotic therapy will decrease Clostridium difficile infection (CDI) recurrence
      as compared to treatment with MK-6072 or MK-3415, 2) treatment with MK-3415A, MK-6072, or
      MK-3415, in addition to SOC antibiotic therapy will decrease CDI recurrence as compared to
      placebo, and 3) MK-3415A, MK-6072, and MK-3415 will be generally well tolerated in
      participants receiving SOC therapy for CDI as compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Clostridium Difficile Infection (CDI) Recurrence</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic Clostridium (C.) difficile following clinical cure of the initial CDI episode</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Adverse Events (AEs) During 4 Weeks Following Infusion</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Any Drug-related AE During 4 Weeks Following Infusion</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE was an AE determined by the investigator to be related to the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Any Serious Adverse Events (SAEs) During 4 Weeks Following Infusion</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>A SAE is any AE occurring at any dose or during any use of Sponsor's product that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer, or is associated with an overdose (whether accidental or intentional); or is other important medical events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Any Serious Drug-related Adverse Events During 4 Weeks Following Infusion</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>A SAE is any AE occurring at any dose or during any use of Sponsor's product that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer, or is associated with an overdose (whether accidental or intentional); or is other important medical events. A serious drug-related AE was a SAE determined by the investigator to be related to the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Medication Due to an AE During 4 Weeks Following Infusion</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol-specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Infusion-specific AEs</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Infusion-specific AEs included local infusion site AEs; and systemic AEs which include nausea, vomiting, chills, fatigue, feeling hot, infusion site conditions (bruising, coldness, erythema, extravasation, pain, phlebitis, pruritus), pyrexia, arthralgia, musculoskeletal pain, myalgia, dizziness, headache, dysphonia, nasal congestion, pruritus, rash, pruritic rash, urticaria, flushing, hot flush, hypertension, and hypotension.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Global Cure</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Global Cure is defined as the clinical cure of the initial CDI episode and no CDI recurrence through Week 12. Clinical cure is defined as participants who received ≤ 14 day regimen of SOC therapy and have no diarrhea (≤2 loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the initial CDI episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CDI Recurrence in Those With Clinical Cure of the Initial CDI Episode</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Clinical cure is defined as participants who received ≤ 14 day regimen of SOC therapy and have no diarrhea (≤2 loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the baseline CDI episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants ≥ 65 Years of Age at Study Entry With CDI Recurrence</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a History of CDI in the 6 Months Prior to Enrollment With CDI Recurrence</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Severe CDI at Study Entry With CDI Recurrence</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Clinically severe CDI is defined as a Zar Score ≥ 2 based on the presence of 1 or more of the following: 1) age &gt;60 years old (1 point); 2)body temperature &gt;38.3°C (&gt;100°F) (1 point); 3) albumin level ˂2.5 mg/dL (1 point); 4) peripheral white blood cell count &gt;15,000 cells/mm^3 within 48 hours (1 point); 5) endoscopic evidence of pseudomembranous colitis (2 points); and 6) treatment in Intensive Care Unit (2 points).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the B1/NAP1/027 Strain of C. Difficile at Study Entry With CDI Recurrence</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Epidemic Strain of C. Difficile (Ribotypes 027, 014, 002, 001, 106, and 020) at Study Entry With CDI Recurrence</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Compromised Immunity at Study Entry With CDI Recurrence</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Compromised immunity is defined as follows: an active hematological malignancy (including leukemia, lymphoma, multiple myeloma), an active malignancy requiring recent cytotoxic chemotherapy, receipt of a prior hematopoietic stem cell transplant, receipt of a prior solid organ transplant, asplenia, or neutropenia/pancytopenia due to other conditions.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1452</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>MK-3415 + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-6072 + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-3415A + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-3415</intervention_name>
    <description>A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)</description>
    <arm_group_label>MK-3415 + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-6072</intervention_name>
    <description>A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)</description>
    <arm_group_label>MK-6072 + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-3415A</intervention_name>
    <description>A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)</description>
    <arm_group_label>MK-3415A + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single IV infusion of normal saline (0.9% sodium chloride)</description>
    <arm_group_label>Placebo + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC</intervention_name>
    <description>Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.</description>
    <arm_group_label>MK-3415 + SOC</arm_group_label>
    <arm_group_label>MK-6072 + SOC</arm_group_label>
    <arm_group_label>MK-3415A + SOC</arm_group_label>
    <arm_group_label>Placebo + SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  participant has a confirmed diagnosis of CDI as defined by: a. diarrhea, as defined by
             passage of 3 or more loose stools in 24 or fewer hours, AND b. A positive test for
             toxigenic C. difficile from a stool collected no more than 7 days before study
             infusion.

          -  participant must be receiving SOC therapy for CDI. SOC therapy is defined as the
             receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral
             vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.

          -  participant is highly unlikely to become pregnant or to impregnate a partner since
             they meet at least one of the following criteria: a. A female participant who is not
             of reproductive potential is eligible without requiring the use of contraception. A
             female participant who is not of reproductive potential is defined as: one who has
             either (1) reached natural menopause (defined as 6 months of spontaneous amenorrhea
             with serum follicle stimulating hormone (FSH) levels in the postmenopausal range as
             determined by the local laboratory, or 12 months of spontaneous amenorrhea); (2) 6
             weeks post surgical bilateral oophorectomy with or without hysterectomy; or (3)
             bilateral tubal ligation. Spontaneous amenorrhea does not include cases for which
             there is an underlying disease that causes amenorrhea (e.g. anorexia nervosa). b. A
             participant who is of reproductive potential agrees to remain abstinent or use (or
             have their partner use) 2 acceptable methods of birth control starting at enrollment
             and through the 12 Week study period. Acceptable methods of birth control are:
             intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom,
             vasectomy and any registered and marketed hormonal contraceptives that contain an
             estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or
             intramuscular agents)

          -  participant or legal representative must have voluntarily agreed to participate by
             providing written informed consent after the nature of the study has been fully
             explained.

        Exclusion Criteria:

          -  participant with an uncontrolled chronic diarrheal illness such that their normal
             24-hour bowel movement habit is 3 or more loose stools.

          -  participant with a planned surgery for CDI within 24 hours.

          -  participant has a positive pregnancy test in the 48 hours before the infusion or is
             unwilling to undergo pregnancy testing if a pre-menopausal female who is not
             sterilized and therefore has the potential to bear a child.

          -  participant is breast-feeding or plans to breast-feed prior to the completion of the
             12-week study period.

          -  A female participant who plans to donate ova prior to the completion of the 12-week
             study period, or a male participant who is planning to impregnate or provide sperm
             donation prior to the completion of the 12-week study period.

          -  participant has previously participated in this study, has previously received MK-3415
             or MK- 6072 (either alone or in combination), has received a C. difficile vaccine, or
             has received another experimental monoclonal antibody against C. difficile toxin A or
             B.

          -  participant plans to donate blood and/or blood products within 6 months following the
             infusion.

          -  participant has received immune globulin within 6 months prior to receipt of the
             infusion or is planning to receive immune globulin prior to the completion of the
             12-week study period.

          -  treatment with SOC therapy is planned for longer than 14 days.

          -  participant has received more than a 24-hour regimen of cholestyramine, colestimide,
             rifaximin, or nitazoxanide within 14 days prior to receipt of the infusion or is
             planning to receive these medications prior to the completion of the 12-week study
             period.

          -  participant plans to take medications that are given to decrease gastrointestinal
             peristalsis, such as loperamide (Imodium™) or diphenoxylate hydrochloride/atropine
             sulfate (LOMOTIL™), at any time during the 14 days following infusion. Participants
             receiving opioid medications at the onset of diarrhea may be included if they are on a
             stable dose or if there is anticipation of a dose decrease or cessation of use.

          -  participant plans to take the probiotic Saccharomyces boulardii or receive fecal
             transplant therapy, or any other therapies that have been demonstrated to decrease CDI
             recurrences at any time following infusion (Day 1) and through the completion of the
             12-week study period.

          -  participant has received another investigational study agent within the previous 30
             days, or is currently participating in or scheduled to participate in any other
             clinical trial with an investigational agent during the 12-week study period.

          -  participant is not expected to survive for 72 hours.

          -  participant has any other condition that, in the opinion of the investigator, would
             jeopardize the safety or rights of the participant participating in the study, would
             make it unlikely for the participant to complete the study, or would confound the
             results of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <results_first_submitted>October 24, 2016</results_first_submitted>
  <results_first_submitted_qc>October 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2016</results_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium difficile</keyword>
  <keyword>recurrent Clostridium difficile</keyword>
  <keyword>vancomycin</keyword>
  <keyword>metronidazole</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>Clostridium difficile infection (CDI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants 18 years of age or older, with a diagnosis of Clostridium difficile Infection (CDI) were enrolled in this trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MK-3415 + SOC</title>
          <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care (SOC) for CDI</description>
        </group>
        <group group_id="P2">
          <title>MK-6072 + SOC</title>
          <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
        </group>
        <group group_id="P3">
          <title>MK-3415A + SOC</title>
          <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
        </group>
        <group group_id="P4">
          <title>Placebo + SOC</title>
          <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="403"/>
                <participants group_id="P3" count="403"/>
                <participants group_id="P4" count="404"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="392"/>
                <participants group_id="P3" count="388"/>
                <participants group_id="P4" count="397"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="340"/>
                <participants group_id="P3" count="343"/>
                <participants group_id="P4" count="340"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="64"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical Problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-3415 + SOC</title>
          <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
        </group>
        <group group_id="B2">
          <title>MK-6072 + SOC</title>
          <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
        </group>
        <group group_id="B3">
          <title>MK-3415A + SOC</title>
          <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
        </group>
        <group group_id="B4">
          <title>Placebo + SOC</title>
          <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="242"/>
            <count group_id="B2" value="403"/>
            <count group_id="B3" value="403"/>
            <count group_id="B4" value="404"/>
            <count group_id="B5" value="1452"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="16.8"/>
                    <measurement group_id="B2" value="61.1" spread="18.5"/>
                    <measurement group_id="B3" value="62.5" spread="17.8"/>
                    <measurement group_id="B4" value="62.9" spread="18.3"/>
                    <measurement group_id="B5" value="62.5" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="224"/>
                    <measurement group_id="B4" value="230"/>
                    <measurement group_id="B5" value="829"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="174"/>
                    <measurement group_id="B5" value="623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Clostridium Difficile Infection (CDI) Recurrence</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic Clostridium (C.) difficile following clinical cure of the initial CDI episode</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clostridium Difficile Infection (CDI) Recurrence</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic Clostridium (C.) difficile following clinical cure of the initial CDI episode</description>
          <population>Participants who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="386"/>
                <count group_id="O3" value="383"/>
                <count group_id="O4" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9"/>
                    <measurement group_id="O2" value="17.4"/>
                    <measurement group_id="O3" value="15.9"/>
                    <measurement group_id="O4" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3182</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.6</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-10.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.9</ci_lower_limit>
            <ci_upper_limit>-4.3</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-11.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.4</ci_lower_limit>
            <ci_upper_limit>-5.9</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.9</ci_lower_limit>
            <ci_upper_limit>-3.4</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-3415A + SOC - MK-3415 + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2997</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-3415A + SOC - MK-6072 + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Global Cure</title>
        <description>Global Cure is defined as the clinical cure of the initial CDI episode and no CDI recurrence through Week 12. Clinical cure is defined as participants who received ≤ 14 day regimen of SOC therapy and have no diarrhea (≤2 loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the initial CDI episode.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Global Cure</title>
          <description>Global Cure is defined as the clinical cure of the initial CDI episode and no CDI recurrence through Week 12. Clinical cure is defined as participants who received ≤ 14 day regimen of SOC therapy and have no diarrhea (≤2 loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the initial CDI episode.</description>
          <population>Participants who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="386"/>
                <count group_id="O3" value="383"/>
                <count group_id="O4" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0"/>
                    <measurement group_id="O2" value="60.1"/>
                    <measurement group_id="O3" value="58.7"/>
                    <measurement group_id="O4" value="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9775</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-8.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.3</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0861</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>11.7</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1646</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>10.4</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>11.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.5</ci_lower_limit>
            <ci_upper_limit>19.7</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-3415A + SOC - MK-3415 + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6532</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.3</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-3415A + SOC - MK-6072 + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CDI Recurrence in Those With Clinical Cure of the Initial CDI Episode</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Clinical cure is defined as participants who received ≤ 14 day regimen of SOC therapy and have no diarrhea (≤2 loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the baseline CDI episode.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; complied with Good Clinical Practice; and achieved clinical cure of the initial CDI episode.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CDI Recurrence in Those With Clinical Cure of the Initial CDI Episode</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Clinical cure is defined as participants who received ≤ 14 day regimen of SOC therapy and have no diarrhea (≤2 loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the baseline CDI episode.</description>
          <population>Participants who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; complied with Good Clinical Practice; and achieved clinical cure of the initial CDI episode.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="299"/>
                <count group_id="O3" value="286"/>
                <count group_id="O4" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="22.4"/>
                    <measurement group_id="O3" value="21.3"/>
                    <measurement group_id="O4" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6505</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-10.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.7</ci_lower_limit>
            <ci_upper_limit>-3.8</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-11.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.6</ci_lower_limit>
            <ci_upper_limit>-4.7</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-13.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.5</ci_lower_limit>
            <ci_upper_limit>-5.2</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-3415A + SOC - MK-3415 + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3906</p_value>
            <p_value_desc>One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted Difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
            <estimate_desc>Adjusted Difference: MK-3415A + SOC - MK-6072 + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With One or More Adverse Events (AEs) During 4 Weeks Following Infusion</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an AE.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Adverse Events (AEs) During 4 Weeks Following Infusion</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an AE.</description>
          <population>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="387"/>
                <count group_id="O4" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2"/>
                    <measurement group_id="O2" value="65.4"/>
                    <measurement group_id="O3" value="59.7"/>
                    <measurement group_id="O4" value="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.185</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>12.8</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.323</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.507</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Any Drug-related AE During 4 Weeks Following Infusion</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an AE. A drug-related AE was an AE determined by the investigator to be related to the drug.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Drug-related AE During 4 Weeks Following Infusion</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an AE. A drug-related AE was an AE determined by the investigator to be related to the drug.</description>
          <population>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="387"/>
                <count group_id="O4" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="8.2"/>
                    <measurement group_id="O3" value="6.2"/>
                    <measurement group_id="O4" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.246</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>6.7</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.464</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Any Serious Adverse Events (SAEs) During 4 Weeks Following Infusion</title>
        <description>A SAE is any AE occurring at any dose or during any use of Sponsor’s product that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer, or is associated with an overdose (whether accidental or intentional); or is other important medical events.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Serious Adverse Events (SAEs) During 4 Weeks Following Infusion</title>
          <description>A SAE is any AE occurring at any dose or during any use of Sponsor’s product that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer, or is associated with an overdose (whether accidental or intentional); or is other important medical events.</description>
          <population>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="387"/>
                <count group_id="O4" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                    <measurement group_id="O2" value="21.5"/>
                    <measurement group_id="O3" value="14.7"/>
                    <measurement group_id="O4" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.594</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>7.2</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.051</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.6</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Any Serious Drug-related Adverse Events During 4 Weeks Following Infusion</title>
        <description>A SAE is any AE occurring at any dose or during any use of Sponsor’s product that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer, or is associated with an overdose (whether accidental or intentional); or is other important medical events. A serious drug-related AE was a SAE determined by the investigator to be related to the drug.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Serious Drug-related Adverse Events During 4 Weeks Following Infusion</title>
          <description>A SAE is any AE occurring at any dose or during any use of Sponsor’s product that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer, or is associated with an overdose (whether accidental or intentional); or is other important medical events. A serious drug-related AE was a SAE determined by the investigator to be related to the drug.</description>
          <population>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="387"/>
                <count group_id="O4" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.115</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.170</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.544</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415A + SOC - Placeb + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued Study Medication Due to an AE During 4 Weeks Following Infusion</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol-specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an AE.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Medication Due to an AE During 4 Weeks Following Infusion</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol-specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an AE.</description>
          <population>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="387"/>
                <count group_id="O4" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.192</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.311</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.999</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Infusion-specific AEs</title>
        <description>Infusion-specific AEs included local infusion site AEs; and systemic AEs which include nausea, vomiting, chills, fatigue, feeling hot, infusion site conditions (bruising, coldness, erythema, extravasation, pain, phlebitis, pruritus), pyrexia, arthralgia, musculoskeletal pain, myalgia, dizziness, headache, dysphonia, nasal congestion, pruritus, rash, pruritic rash, urticaria, flushing, hot flush, hypertension, and hypotension.</description>
        <time_frame>Up to 24 hours</time_frame>
        <population>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Infusion-specific AEs</title>
          <description>Infusion-specific AEs included local infusion site AEs; and systemic AEs which include nausea, vomiting, chills, fatigue, feeling hot, infusion site conditions (bruising, coldness, erythema, extravasation, pain, phlebitis, pruritus), pyrexia, arthralgia, musculoskeletal pain, myalgia, dizziness, headache, dysphonia, nasal congestion, pruritus, rash, pruritic rash, urticaria, flushing, hot flush, hypertension, and hypotension.</description>
          <population>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="387"/>
                <count group_id="O4" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="11.8"/>
                    <measurement group_id="O3" value="8.8"/>
                    <measurement group_id="O4" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>8.7</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants ≥ 65 Years of Age at Study Entry With CDI Recurrence</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants ≥ 65 years of age at study entry who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants ≥ 65 Years of Age at Study Entry With CDI Recurrence</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.</description>
          <population>Participants ≥ 65 years of age at study entry who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="15.1"/>
                    <measurement group_id="O3" value="17.0"/>
                    <measurement group_id="O4" value="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-6.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.8</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-18.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.3</ci_lower_limit>
            <ci_upper_limit>-9.6</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-16.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.5</ci_lower_limit>
            <ci_upper_limit>-7.7</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a History of CDI in the 6 Months Prior to Enrollment With CDI Recurrence</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants with a history of CDI in the 6 months prior to enrollment who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a History of CDI in the 6 Months Prior to Enrollment With CDI Recurrence</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.</description>
          <population>Participants with a history of CDI in the 6 months prior to enrollment who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="26.2"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.1</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-13.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.5</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-14.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.8</ci_lower_limit>
            <ci_upper_limit>-1.6</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinically Severe CDI at Study Entry With CDI Recurrence</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Clinically severe CDI is defined as a Zar Score ≥ 2 based on the presence of 1 or more of the following: 1) age &gt;60 years old (1 point); 2)body temperature &gt;38.3°C (&gt;100°F) (1 point); 3) albumin level ˂2.5 mg/dL (1 point); 4) peripheral white blood cell count &gt;15,000 cells/mm^3 within 48 hours (1 point); 5) endoscopic evidence of pseudomembranous colitis (2 points); and 6) treatment in Intensive Care Unit (2 points).</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants with clinically severe CDI at study entry who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Severe CDI at Study Entry With CDI Recurrence</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Clinically severe CDI is defined as a Zar Score ≥ 2 based on the presence of 1 or more of the following: 1) age &gt;60 years old (1 point); 2)body temperature &gt;38.3°C (&gt;100°F) (1 point); 3) albumin level ˂2.5 mg/dL (1 point); 4) peripheral white blood cell count &gt;15,000 cells/mm^3 within 48 hours (1 point); 5) endoscopic evidence of pseudomembranous colitis (2 points); and 6) treatment in Intensive Care Unit (2 points).</description>
          <population>Participants with clinically severe CDI at study entry who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="10.4"/>
                    <measurement group_id="O3" value="12.9"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.9</ci_lower_limit>
            <ci_upper_limit>21.0</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-14.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.3</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-12.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.2</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With the B1/NAP1/027 Strain of C. Difficile at Study Entry With CDI Recurrence</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants with the B1/NAP1/027 strain of C. difficile at study entry who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the B1/NAP1/027 Strain of C. Difficile at Study Entry With CDI Recurrence</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.</description>
          <population>Participants with the B1/NAP1/027 strain of C. difficile at study entry who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="26.1"/>
                    <measurement group_id="O3" value="10.8"/>
                    <measurement group_id="O4" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-10.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.1</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-25.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.7</ci_lower_limit>
            <ci_upper_limit>-6.1</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Epidemic Strain of C. Difficile (Ribotypes 027, 014, 002, 001, 106, and 020) at Study Entry With CDI Recurrence</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants with an epidemic strain of C. difficile at study entry who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Epidemic Strain of C. Difficile (Ribotypes 027, 014, 002, 001, 106, and 020) at Study Entry With CDI Recurrence</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.</description>
          <population>Participants with an epidemic strain of C. difficile at study entry who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="19.8"/>
                    <measurement group_id="O4" value="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-11.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.9</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-12.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.7</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-16.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.8</ci_lower_limit>
            <ci_upper_limit>-4.0</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Compromised Immunity at Study Entry With CDI Recurrence</title>
        <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Compromised immunity is defined as follows: an active hematological malignancy (including leukemia, lymphoma, multiple myeloma), an active malignancy requiring recent cytotoxic chemotherapy, receipt of a prior hematopoietic stem cell transplant, receipt of a prior solid organ transplant, asplenia, or neutropenia/pancytopenia due to other conditions.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants with compromised immunity at study entry who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-3415 + SOC</title>
            <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI</description>
          </group>
          <group group_id="O2">
            <title>MK-6072 + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI</description>
          </group>
          <group group_id="O3">
            <title>MK-3415A + SOC</title>
            <description>Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI</description>
          </group>
          <group group_id="O4">
            <title>Placebo + SOC</title>
            <description>Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Compromised Immunity at Study Entry With CDI Recurrence</title>
          <description>CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Compromised immunity is defined as follows: an active hematological malignancy (including leukemia, lymphoma, multiple myeloma), an active malignancy requiring recent cytotoxic chemotherapy, receipt of a prior hematopoietic stem cell transplant, receipt of a prior solid organ transplant, asplenia, or neutropenia/pancytopenia due to other conditions.</description>
          <population>Participants with compromised immunity at study entry who received infusion of study medication; had a positive local stool test for toxigenic C. difficile; received protocol defined standard of care therapy within 1 day window of the infusion; and complied with Good Clinical Practice.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="17.2"/>
                    <measurement group_id="O3" value="11.5"/>
                    <measurement group_id="O4" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-10.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.2</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-11.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.2</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-6072 + SOC - Placebo + SOC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-16.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.4</ci_lower_limit>
            <ci_upper_limit>-4.7</ci_upper_limit>
            <estimate_desc>Percentage Difference: MK-3415A + SOC - Placebo + SOC</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 90 days</time_frame>
      <desc>All randomized participants who received infusion of study medication, based on the treatment actually received. One participant randomized to receive MK-3415A, and two participants randomized to receive MK-6072 actually received placebo instead.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-3415 + SOC</title>
          <description>Single intravenous (IV) infusion of 10 mg/kg MK-3415 + SOC for CDI</description>
        </group>
        <group group_id="E2">
          <title>MK-6072 + SOC</title>
          <description>Single IV infusion of 10 mg/kg MK-6072 + SOC for CDI</description>
        </group>
        <group group_id="E3">
          <title>MK-3415A + SOC</title>
          <description>Single IV infusion of 10 mg/kg MK 3415A + SOC for CDI</description>
        </group>
        <group group_id="E4">
          <title>Placebo + SOC</title>
          <description>Normal saline infusion (0.9% sodium chloride) + SOC for CDI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="387"/>
                <counts group_id="E4" subjects_affected="126" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="235"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Intrapericardial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="235"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="235"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="390"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="387"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Epiploic appendagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Gastritis alcoholic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Intestinal dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cirrhosis alcoholic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft versus host disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Acute graft versus host disease in intestine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in gastrointestinal tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Heart transplant rejection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="235"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="390"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="387"/>
                <counts group_id="E4" events="32" subjects_affected="26" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Clostridium difficile sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Gas gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hypopyon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Infected lymphocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="235"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="390"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="387"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="235"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="390"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="235"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Systemic mycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="235"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="390"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Zygomycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Perinephric collection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Procedural vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Radiation oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hyperammonaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Connective tissue disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Burkitt's lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hypergammaglobulinaemia benign monoclonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Psychogenic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Nephritis autoimmune</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="235"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="390"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pharyngeal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pulmonary cavitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="387"/>
                <counts group_id="E4" subjects_affected="103" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="235"/>
                <counts group_id="E2" events="32" subjects_affected="25" subjects_at_risk="390"/>
                <counts group_id="E3" events="21" subjects_affected="20" subjects_at_risk="387"/>
                <counts group_id="E4" events="28" subjects_affected="24" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="235"/>
                <counts group_id="E2" events="33" subjects_affected="25" subjects_at_risk="390"/>
                <counts group_id="E3" events="38" subjects_affected="33" subjects_at_risk="387"/>
                <counts group_id="E4" events="42" subjects_affected="27" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="235"/>
                <counts group_id="E2" events="38" subjects_affected="32" subjects_at_risk="390"/>
                <counts group_id="E3" events="40" subjects_affected="33" subjects_at_risk="387"/>
                <counts group_id="E4" events="35" subjects_affected="30" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="235"/>
                <counts group_id="E2" events="29" subjects_affected="23" subjects_at_risk="390"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="387"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="235"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="390"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="387"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="235"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="390"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="387"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="235"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="390"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="387"/>
                <counts group_id="E4" events="21" subjects_affected="20" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="235"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="390"/>
                <counts group_id="E3" events="23" subjects_affected="22" subjects_at_risk="387"/>
                <counts group_id="E4" events="18" subjects_affected="14" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

